LRRK2 and Parkinson disease: Considering that most pathogenic LRRK2 mutations lead to increased phosphorylation of its substrates, either by upregulation of kinase activity or enhanced substrate binding, and that Rab29 activates LRRK2, our data is in line with this view and might further link the abnormalities in Rab29 with PD in terms of pathological mechanisms.